Investment Thesis
Arcus Biosciences shows exceptional revenue growth (648.5% YoY) suggesting recent product commercialization, but is burning cash at unsustainable rates (-$138M operating loss on only $17M revenue) with approximately 1.5-2 years of cash runway remaining. While the balance sheet is currently solid with strong liquidity and modest debt, the company requires dramatic operating margin improvement or continued capital raises to survive long-term.
Strengths
- Exceptional revenue growth of 648.5% YoY indicating successful product launch or market penetration
- Strong liquidity position (4.04x current ratio) and $201M cash reserves provide operational runway
- Conservative leverage (0.19x debt/equity ratio) maintains financial flexibility for potential capital raises
Risks
- Unsustainable operating burn rate of -$138M annually on only $17M revenue creates severe near-term cash depletion risk
- At current burn rates, cash runway extends only 12-18 months before depletion or required capital raise
- Deeply negative margins (-788.2% operating margin) indicate company has not yet achieved viable unit economics despite growth
- Pharmaceutical sector execution risk: future viability depends entirely on pipeline success, regulatory approvals, and ability to scale profitably
Key Metrics to Watch
- Quarterly revenue growth trajectory and gross margins (actual profitability at product level)
- Operating expense burn rate reduction and path to profitability timeline
- Remaining cash runway and potential need for capital raise
- Clinical pipeline progress, regulatory milestones, and product commercialization expansion
Financial Metrics
Revenue
17.0M
Net Income
-128.0M
EPS (Diluted)
$-1.02
Free Cash Flow
-138.0M
Total Assets
997.0M
Cash
201.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-788.2%
Net Margin
-752.9%
ROE
-24.4%
ROA
-12.8%
FCF Margin
-811.8%
Balance Sheet & Liquidity
Current Ratio
4.04x
Quick Ratio
4.04x
Debt/Equity
0.19x
Debt/Assets
69.7%
Interest Coverage
-44.67x
Long-term Debt
100.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-07T10:22:07.729162 |
Data as of: 2026-03-31 |
Powered by Claude AI